全文获取类型
收费全文 | 838篇 |
免费 | 55篇 |
专业分类
893篇 |
出版年
2022年 | 6篇 |
2018年 | 11篇 |
2017年 | 6篇 |
2016年 | 10篇 |
2015年 | 15篇 |
2014年 | 27篇 |
2013年 | 31篇 |
2012年 | 44篇 |
2011年 | 49篇 |
2010年 | 24篇 |
2009年 | 34篇 |
2008年 | 50篇 |
2007年 | 41篇 |
2006年 | 31篇 |
2005年 | 27篇 |
2004年 | 28篇 |
2003年 | 27篇 |
2002年 | 33篇 |
2001年 | 25篇 |
2000年 | 24篇 |
1999年 | 19篇 |
1998年 | 15篇 |
1997年 | 9篇 |
1996年 | 10篇 |
1995年 | 10篇 |
1994年 | 11篇 |
1993年 | 13篇 |
1992年 | 20篇 |
1991年 | 11篇 |
1990年 | 15篇 |
1989年 | 11篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1982年 | 7篇 |
1981年 | 8篇 |
1980年 | 6篇 |
1979年 | 11篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1975年 | 9篇 |
1973年 | 8篇 |
1971年 | 9篇 |
1970年 | 8篇 |
1968年 | 6篇 |
1967年 | 6篇 |
1966年 | 6篇 |
1965年 | 5篇 |
排序方式: 共有893条查询结果,搜索用时 0 毫秒
111.
112.
113.
Yahata K Kishine H Sone T Sasaki Y Hotta J Chesnut JD Okabe M Imamoto F 《Journal of biotechnology》2005,118(2):123-134
Using Multisite Gateway five-DNA-fragment constructs vectors that enable expression of two tandemly situated cDNAs on a single plasmid were developed. Heterologous protein production in cells was achieved by modulating respective cDNA expression to pre-determined and different levels. Optimization of cDNA expression at near physiological protein levels was achieved using promoters from four cell cycle-dependent genes. In comparison with conventionally available promoters, EF-1alpha or CMV, the promoters used in this study were able to modulate cDNA expression levels over a magnitude of approximately 10 or 100-fold, respectively. In transiently transfected cells, two different proteins (CPalpha1 and CPbeta2), which form a heterodimer, each labeled with a different-colored fluorescent protein, were successfully synthesized at pre-determined levels from their respective cDNAs. The above vectors were designed to contain an FRT/Flp recombination site for integration onto chromosomes and for establishment of stable clones in HeLa cells by site-specific recombination. In the stable transformant cells produced only about 4% of the protein production levels measured in the transiently transformed cells. The biological significance of these observations is discussed. 相似文献
114.
p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate 总被引:6,自引:0,他引:6
Kunisaki R Ikawa S Maeda T Nakazaki Y Kurita R Harata M Shutoh Y Bai YS Soda Y Tanabe T Dohi T Kato R Ikawa Y Asano S Tani K 《The journal of gene medicine》2006,8(9):1121-1130
BACKGROUND: p51 (p73L/p63/p40/KET), a recently isolated novel p53 homologue, binds to p53-responsive elements to upregulate some p53 target genes and has been suggested to share partially overlapping functions with p53. p51 may be a promising candidate target molecule for anti-cancer therapy. METHODS: In this study, we adenovirally transduced p51A cDNA into human lung, gastric and pancreatic cancer cells and analyzed the intracellular function of p51 in anti-oncogenesis in vitro and in vivo. RESULTS: Overexpression of p51A revealed an anti-proliferative effect in vitro in all the cancer cells examined in this study. The anchorage-dependent and -independent cell growth of EBC1 cells carrying mutations in both p51 and p53 was suppressed and significant apoptosis following adenoviral transduction with p51 and/or p53 was seen. This growth suppression was cooperatively enhanced by the combined infection with adenoviral vectors encoding both p51 and p53. Furthermore, p51 activated several, but not all, p53-inducible genes, indicating that the mechanisms controlling p51- and p53-mediated tumor suppression differed. CONCLUSIONS: Our observations indicate that, although p51 exhibited reduced anti-oncogenetic effects compared with p53, it cooperatively enhanced the anti-tumor effects of p53. Our results suggest that p51 functions as a tumor suppressor in human cancer cells in vitro and in vivo and may be useful as a potential tool for cancer gene therapy. 相似文献
115.
El-Shamy A Shoji I Kim SR Ide Y Imoto S Deng L Yoon S Fujisawa T Tani S Yano Y Seo Y Azuma T Hotta H 《PloS one》2012,7(2):e30513
Pegylated-interferon plus ribavirin (PEG-IFN/RBV) therapy is a current standard treatment for chronic hepatitis C. We previously reported that the viral sequence heterogeneity of part of NS5A, referred to as the IFN/RBV resistance-determining region (IRRDR), and a mutation at position 70 of the core protein of hepatitis C virus genotype 1b (HCV-1b) are significantly correlated with the outcome of PEG-IFN/RBV treatment. Here, we aimed to investigate the impact of viral genetic variations within the NS5A and core regions of other genotypes, HCV-2a and HCV-2b, on PEG-IFN/RBV treatment outcome. Pretreatment sequences of NS5A and core regions were analyzed in 112 patients infected with HCV-2a or HCV-2b, who were treated with PEG-IFN/RBV for 24 weeks and followed up for another 24 weeks. The results demonstrated that HCV-2a isolates with 4 or more mutations in IRRDR (IRRDR[2a]≥4) was significantly associated with rapid virological response at week 4 (RVR) and sustained virological response (SVR). Also, another region of NS5A that corresponds to part of the IFN sensitivity-determining region (ISDR) plus its carboxy-flanking region, which we referred to as ISDR/+C[2a], was significantly associated with SVR in patients infected with HCV-2a. Multivariate analysis revealed that IRRDR[2a]≥4 was the only independent predictive factor for SVR. As for HCV-2b infection, an N-terminal half of IRRDR having two or more mutations (IRRDR[2b]/N≥2) was significantly associated with RVR, but not with SVR. No significant correlation was observed between core protein polymorphism and PEG-IFN/RBV treatment outcome in HCV-2a or HCV-2b infection. CONCLUSION: The present results suggest that sequence heterogeneity of NS5A of HCV-2a (IRRDR[2a]≥4 and ISDR/+C[2a]), and that of HCV-2b (IRRDR[2b]/N≥2) to a lesser extent, is involved in determining the viral sensitivity to PEG-IFN/RBV therapy. 相似文献
116.
117.
118.
119.
120.